IP Verse

Dosing Regimen For A Selective S1P1 Receptor Agonist - EP3256125

The patent EP3256125 was granted to Actelion Pharmaceuticals on Jan 26, 2022. The application was originally filed on Dec 10, 2015 under application number EP15807916A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3256125

ACTELION PHARMACEUTICALS
Application Number
EP15807916A
Filing Date
Dec 10, 2015
Status
Granted And Under Opposition
Dec 24, 2021
Publication Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELOct 26, 2022HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSOct 21, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005054215
DESCRIPTIONWO2008062376
DESCRIPTIONWO2009115954
DESCRIPTIONWO2010046835
DESCRIPTIONWO2014027330
INTERNATIONAL-SEARCH-REPORTWO2009115954
OPPOSITIONWO2009115954

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (2013), vol. 76, no. 6, pages 888 - 896
DESCRIPTION- OLSSON T. ET AL., "Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial", J NEUROL NEUROSURG PSYCHIATRY, (2014), vol. 85, no. 11, pages 1198 - 1208
DESCRIPTION- VACLAVKOVA A. ET AL., "Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial", LANCET, (2014), vol. 384, no. 9959, pages 2036 - 2045
INTERNATIONAL-SEARCH-REPORT- BROSSARD P ET AL, "Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.", JOURNAL OF CLINICAL PHARMACOLOGY FEB 2014, (201402), vol. 54, no. 2, ISSN 1552-4604, pages 179 - 188, XP002754016 [I] 1-11 * abstract * * page 180, column left, line 40 - line 47 * * page 187, column right, line 22 - line 25 *
INTERNATIONAL-SEARCH-REPORT- HOCH M ET AL, "A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator", CLINICAL THERAPEUTICS, (20150801), vol. 37, no. 8, doi:10.1016/J.CLINTHERA.2015.05.114, ISSN 0149-2918, XP029181237 [IP] 1-11 * page e36, column right, line 50 - page e37, column left, line 26 *
INTERNATIONAL-SEARCH-REPORT- REY MARKUS ET AL, "Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator", PLOS ONE, (20130912), vol. 8, no. 9, doi:10.1371/journal.pone.0074285, pages 1 - 7, XP002754017 [I] 1-11 * abstract * * page 1, column left, lines 1-3 *
OPPOSITION- Basile Jan N., "Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events", Postgraduate Medicine, (20030301), vol. 113, no. 3, pages 63 - 70, XP055980347
OPPOSITION- Brossard P., D'ambrosio D., Ipak M., Dingemanse J., "P468 - Effects on heart rate of three different up-titration regimens of ponesimod, a selective S1P1 receptor modulator, and of re-initiation of treatment inhealthy male and female subjects", Multiple Sclerosis Journal, (20121001), vol. 18, no. S4, page 192, XP055980327
OPPOSITION- De Vries T.P.G.M., Henning R.H., Hogerzeil H.V., Fresle D.A., "Annex 1 - Essentials of pharmacology in daily practice", Guide to Good Prescribing - A practical manual, (19980101), pages 98 - 104, XP055980341
OPPOSITION- James P. Mc Cormack, G. Michael Allan Md, Adil S. Virani, "Is Bigger Better? An argument for very low starting doses", CMAJ, (20110111), vol. 183, no. 1, pages 65 - 69, XP055913813
OPPOSITION- Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J., "Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.", Journal of clinical pharmacology, US , (20140201), vol. 54, no. 2, doi:10.1002/jcph.244, ISSN 1552-4604, pages 179 - 188, XP002754016
OPPOSITION- Scherz Michael W., Brossard Patrick, D'ambrosio Daniele, Ipek Murat, Dingemanse Jasper, "Three different up-titration regimens of ponesimod, an S1P 1 receptor modulator, in healthy subjects : Journal of Clinical Pharmacology", The Journal of clinical pharmacology, US , (20150601), vol. 55, no. 6, doi:10.1002/jcph.467, ISSN 0091-2700, pages 688 - 697, XP055980306
OPPOSITION- Hoch M.; Vaclavkova A.; Krause A.; Strong A.; Bush J.; Dingemanse J.; Juif Pierre-Eric, "A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator", Clinical Therapeutics, AMSTERDAM, NL, (19000101), vol. 37, no. 8, doi:10.1016/j.clinthera.2015.05.114, ISSN 0149-2918, XP029181237
OPPOSITION- T. Olsson, Boster A., Fernandez O., Freedman M. S., Pozzilli C., Bach D., Berkani O., Mueller M. S., Sidorenko T., Radue E.-W., Melanson M., "Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY, GB , (20141101), vol. 85, no. 11, doi:10.1136/jnnp-2013-307282, ISSN 0022-3050, pages 1198 - 1208, XP055734579
OPPOSITION- Rey M, Hess P, Clozel M, Delahaye S, Gatfield J, Nayler O, Steiner B., "Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator.", PLOS ONE, US , (20130901), vol. 8, no. 9, doi:10.1371/journal.pone.0074285, ISSN 1932-6203, pages e74285-1 - e74285-7, XP002754017

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents